Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative analgesia after TACE in hepatocellular carcinoma
ChiCTR2300072923Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in postoperative pain, hepatocellular carcinoma (HCC), anxiety disorder and 1 more (3 arms), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: Incidence of moderate and severe pain. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postoperative painhepatocellular carcinoma (HCC)anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2300072923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072923.